Jazz Pharma to acquire Actio Biosciences for up to $1.3 billion, adding experimental KCNT1 epilepsy drug

Jazz Pharmaceuticals announced it will purchase Actio Biosciences, paying $820 million in cash with up to $500 million in milestone payments. The deal is expected to close by the end of the year.

The acquisition gives Jazz access to ABS-1230, a clinical‑stage small‑molecule designed for KCNT1+ epilepsy, a rare genetic form that affects about 2,500 Americans and has no FDA‑approved therapies.

Early proof‑of‑concept data showed meaningful seizure reductions in children, and the drug is now being studied in the Phase 1b/2a KYRON trial.